Silence Therapeutics PLC
SLN4.750USD
+0.230+5.09%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
224.36MValor de mercado
PerdaP/L TTM
Mais detalhes de Silence Therapeutics PLC Empresa
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Informações de Silence Therapeutics PLC
Código da empresaSLN
Nome da EmpresaSilence Therapeutics PLC
Data de listagemJan 05, 2010
CEOTooman (Craig A)
Número de funcionários116
Tipo de títulosDepository Receipt
Fim do ano fiscalJan 05
Endereço72 Hammersmith Road
CidadeLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalW14 8TH
Telefone442034576900
Sitehttps://www.silence-therapeutics.com/
Código da empresaSLN
Data de listagemJan 05, 2010
CEOTooman (Craig A)
Executivos da empresa Silence Therapeutics PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United Kingdom
43.11M
99.67%
Germany
144.00K
0.33%
USA
0.00
0.00%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 10 de jan
Atualizado em: sáb, 10 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
6.16%
Redmile Group, LLC
4.58%
Lombard Odier Asset Management (USA) Corp.
3.91%
Outro
54.55%
Investidores
Investidores
Proporção
Griffiths (Richard Ian)
24.38%
TCG Crossover Management, LLC
6.42%
Invus Public Equities Advisors, LLC
6.16%
Redmile Group, LLC
4.58%
Lombard Odier Asset Management (USA) Corp.
3.91%
Outro
54.55%
Tipos de investidores
Investidores
Proporção
Individual Investor
24.38%
Investment Advisor
18.45%
Investment Advisor/Hedge Fund
9.97%
Venture Capital
3.35%
Hedge Fund
3.30%
Research Firm
3.11%
Private Equity
2.05%
Bank and Trust
0.01%
Outro
35.37%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
140
18.97M
40.16%
-14.57M
2025Q3
138
19.95M
42.23%
-14.76M
2025Q2
131
33.68M
71.31%
-14.18M
2025Q1
133
31.94M
67.63%
-14.00M
2024Q4
128
31.43M
66.56%
-10.23M
2024Q3
111
35.93M
77.05%
-5.19M
2024Q2
96
34.94M
74.95%
-4.57M
2024Q1
86
35.43M
76.18%
+4.14M
2023Q4
61
30.21M
78.15%
-609.51K
2023Q3
58
32.62M
88.08%
+1.55M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Griffiths (Richard Ian)
11.51M
24.38%
+543.58K
+4.95%
Jun 25, 2025
TCG Crossover Management, LLC
3.03M
6.42%
--
--
Sep 30, 2025
Invus Public Equities Advisors, LLC
2.91M
6.16%
--
--
Sep 30, 2025
Redmile Group, LLC
2.16M
4.58%
--
--
Sep 30, 2025
Lombard Odier Asset Management (USA) Corp.
1.84M
3.91%
-4.79K
-0.26%
Sep 30, 2025
Morgan Stanley & Co. LLC
1.12M
2.37%
-8.39K
-0.74%
Sep 30, 2025
Vivo Capital, LLC
1.11M
2.34%
--
--
Sep 30, 2025
Nantahala Capital Management, LLC
1.04M
2.21%
--
--
Sep 30, 2025
Frazier Life Sciences Management, L.P.
970.13K
2.05%
--
--
Sep 30, 2025
Nextech Invest, Ltd.
952.40K
2.02%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
SPDR S&P International Small Cap ETF
0.01%
ActivePassive International Equity ETF
0%
iShares Biotechnology ETF
0%
Tema Heart & Health ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.87%
ProShares Ultra Nasdaq Biotechnology
Proporção0.03%
Invesco Nasdaq Biotechnology ETF
Proporção0.03%
SPDR S&P International Small Cap ETF
Proporção0.01%
ActivePassive International Equity ETF
Proporção0%
iShares Biotechnology ETF
Proporção0%
Tema Heart & Health ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
